Clinical trials: Margin, Tumor-Free
Clear Cell Renal Cell Carcinoma (ccRCC)
Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM
68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT07768306
- Testing
- 68Ga-NYM096 injection
- Volunteers
- 20 people
- Sponsor
- Norroy Bioscience Co., LTD
Cataract
Comparison of Wound Integrity for Clear Corneal Cataract Incisions
This is a randomized controlled trial to evaluate the safety and efficacy of two different closing methods for clear corneal cataract incisions
- Trial name
- NCT05242653
- Testing
- pressure by a cotton swab, stromal hydration with the balanced salt solution（BSS）
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Endometrial Cancer, Endometrial Adenocarcinoma
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
IMGN853 is designed to inhibit cell division and cell growth of folate receptor 1 (FRα)-expressing tumor cells. The purpose of this study is to test the safety of IMGN853 and bevacizumab and see what effects (good and bad) that…
- Conditions
- Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
- Trial name
- NCT03836157
- Testing
- Mirvetuximab Soravtansine, Bevacizumab
- Where
- United States
- Sponsor
- University of Oklahoma
Renal Cell Carcinoma
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
Inhibition of histone deacetylase (HDAC) provides a novel approach for cancer treatment. LBH589, an oral HDAC inhibitor, has been well tolerated in phase I trials and has shown activity against several types of cancer.
- Trial name
- NCT00550277
- Testing
- LBH589
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Clear Cell Renal Cancer
Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer
When kidney cancer spreads beyond the kidney, it is known as metastatic kidney cancer. This is very difficult to treat and almost all patients will die of their disease within 3 years.
- Trial name
- DEVELOP (NCT01714765)
- Testing
- Dovitinib, Everolimus
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Queen Mary University of London
Renal Cell Carcinoma, Clear Cell
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W)…
- Trial name
- NCT06708949
- Testing
- Drugs Nivolumab, Ipilimumab, BMS-986213 (Relatlimab-Nivolumab FDC)
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
ccRCC
Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment
This study is being performed as a single-arm open-label study in order to provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with advanced ccRCC who have progressed…
- Trial name
- PRELUDE (NCT07460206)
- Testing
- Pembrolizumab 200 mg Q3W, Lenvatinib 20mg QD
- Volunteers
- 108 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled.
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
- Trial name
- NCT06730347
- Testing
- Lorigerlimab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- MacroGenics
Colorectal Cancer
Clear Liquid vs Liberalized Diet in Preparation for Colonoscopy
Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. The death rate from this disease, however, has been decreasing over the last 20 years.
- Trial name
- NCT02621658
- Testing
- Clear Liquid Diet, Full Liquid Diet
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- San Antonio Military Medical Center
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
This phase I trial studies the side effects and the best dose of veliparib when given together with pegylated liposomal doxorubicin hydrochloride, carboplatin, and bevacizumab in treating patients with ovarian cancer, primary…
- Conditions
- Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma
- Trial name
- NCT01459380
- Testing
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis
- Where
- 13 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Postnatal Skin Physiology
Clinical Analysis of the Influence of Using the Skin Care Products on the Diaper Area in Comparison with Using a Cotton Wool Cloth, Moistened with Clear Water on the Skin Physiology of the Newborns from the 1st Day to the 4th Week of Life
Study design: The purpose of the present study is to analyse of the influence of the application of the skin care products on the diaper area (Factor A) and the application of a cotton wool cloth, moistened with clear water on…
- Trial name
- NCT01131403
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Kathrin HILLMANN
Anaplastic Ependymoma, Brain Ependymoma
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
The primary aim of this randomized phase III trial was to study whether the addition of maintenance chemotherapy delivered after surgical resection and focal radiation would be better than surgery and focal radiation alone.
- Conditions
- Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma, Clear Cell Ependymoma
- Trial name
- NCT01096368
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Cisplatin
- Where
- 209 sites in United States, Australia and 2 more
- Volunteers
- 479 people
- Sponsor
- Children's Oncology Group
Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors.
- Conditions
- Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma
- Trial name
- NCT00335556
- Testing
- Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery
- Where
- 187 sites in United States, Australia and 3 more
- Volunteers
- 291 people
- Sponsor
- Children's Oncology Group
Ovarian Neoplasms
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
Regorafenib is an oral multikinase inhibitor that blocks the activity of kinases involved in angiogenesis (VEGFR 1,2,3 and TEK), oncogenesis (KIT, Ret Proto-Oncogene (RET), Raf-1 Proto-Oncogene, Serine/Threonine Kinase (RAF1) and…
- Trial name
- NCT02736305
- Testing
- Regorafenib
- Where
- Singapore
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Aphakia, Cataract
Registry Study on Intraocular Lenses Manufactured by Teleon Surgical B.V.
This is a retrospective, observational (Registry) study aiming to collect safety and performance data on the use of intraocular lenses (IOLs) manufactured by Teleon Surgical B.V. according to routine practice.
- Conditions
- Aphakia, Cataract, Clear Lens Exchange, Refractive Lens Exchange
- Trial name
- NCT05290870
- Testing
- Posterior-chamber intraocular lens
- Where
- Netherlands
- Volunteers
- 2,183 people
- Sponsor
- Teleon Surgical B.V.
Ovarian Cancer, Adverse Effects
Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Patients with early and advanced stages of epithelial ovarian cancer are treated with postoperative systemic chemotherapy after appropriate surgical staging and cytoreductive surgery.
- Trial name
- NCT01824615
- Testing
- Sunitinib
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Cathay General Hospital
Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy
A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy
This study is A prospective，single arm, multicenter clinical study of BTLA monoclonal antibody JS004 (B/T lymphocyte attenuator factor monoclonal antibody) in combination with toripalimab in patients with unresectable or advanced…
- Trial name
- NCT06730932
- Testing
- JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- RenJi Hospital
Bronchiectasis
Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR)
Patients with bronchiectasis (BE) suffer from a persistent cough, daily sputum expectoration, recurrent chest infections, and a poor health-related quality of life.
- Trial name
- CLEAR (NCT04140214)
- Testing
- Hypertonic saline, Carbocysteine 750 MG
- Where
- 20 sites in United Kingdom
- Volunteers
- 288 people
- Sponsor
- Belfast Health and Social Care Trust
Adverse Events
ReSure Sealant Post Approval Study
This is a prospective multicenter observational post-approval registry study that will collect post-approval data relative to the incidence of pre-specified Adverse Ocular Events for cataract surgery patients treated with the…
- Trial name
- Clinical PAS (NCT02310815)
- Testing
- ReSure Sealant
- Volunteers
- 626 people
- Sponsor
- Ocular Therapeutix, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.